Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,406.85 71.57 0.47%
S&P 500 1,672.41 6.12 0.37%
NASDAQ 3,508.10 11.66 0.33%
Ticker Volume Price Price Delta
STOXX 50 2,821.65 -2.85 -0.10%
FTSE 100 6,803.87 48.24 0.71%
DAX 8,472.20 16.37 0.19%
Ticker Volume Price Price Delta
NIKKEI 15,381.02 20.21 0.13%
TOPIX 1,270.39 0.88 0.07%
HANG SENG 23,366.37 -126.66 -0.54%

LILLY (ELI) & COMPANY: Annual Information Update 2012


Press Release

Annual Information Update

Lilly (Eli) & Co

24 January 2013

Eli Lilly and Company


                                (the "Company")                                

Annual Information Update for the 12 months up to and including 24 February
2012.

This Annual Information Update refers to information that has been published or
made available to the public in European Economic Area states and in third
countries in compliance with the Company's obligations under EU and national
laws and rules dealing with the regulation of securities, issuers of securities
and securities markets. The Company is obliged to provide this Annual
Information Update by virtue of having transferable securities listed or
admitted to trading on regulated markets in London.

Neither the Company, nor any other person, takes any responsibility for, or
makes any representation, express or implied, as to the accuracy or
completeness of, the information which this Annual Information Update contains.
This information is not necessarily up to date as at the date of this Annual
Information Update and the Company does not undertake any obligation to update
any such information in the future. Furthermore, such information may have been
prepared in accordance with the laws or regulations of a particular
jurisdiction and may not comply with or meet the relevant standards of
disclosure in any other jurisdiction. This Annual Information Update does not
constitute an offer of any securities addressed to any person and should not be
relied on by any person.

 1. FILINGS IN THE UNITED KINGDOM
    The following documents have been filed with the National Storage Mechanism:
    Filing Date                             Description                        

17 February 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co CHMP

Recommends Approval BYETTA for Use w/Basal Insulin

7 February 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co New Study

Evaluates Cialis® in parallel with Tamsulosin

1 February 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co FDA approves

Jentadueto

1 February 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Reports

Fourth-Quarter and Full-Year 2011 Results

31 January 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Reports

Fourth-Quarter and Full-Year 2011 Results

31 January 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co FDA approves

Jentadueto

24 January 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co Lillys

Agreement to Acquire ChemGen Corp.

5 January 2012 Eli Lilly and Company - DJ Lilly (Eli) & Co 2012 Financial

Guidance

16 December 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Sets

Conference Calls for 2012 Financial Guidance

13 December 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Declares

First-Quarter 2012 Dividend

12 December 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Findings From

Study of JAK2 Inhibitor for Blood Cancers

12 December 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Katherine

Baicker Elected to Lilly Board of Directors

17 November 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Data Shows

Effects of Effient in STEMI Patients

8 November 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly and

Amylin Agree to End Alliance for Exenatide

28 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co ALIMTA

Receives EC Approval

25 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Xigris Recall

- Financial Press Release

25 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Withdrawal of

Xigris

20 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Reports

Third Quarter 2011 Results

18 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Dividend

Declaration - Dividend Declaration

12 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co LVHR Phase III

Study

11 October 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Statement re

Changes in Senior Management - Statement re

27 September 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Alimta - New

Data from Paramount Study

26 September 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Alimta

Receives Positive Opinion from CHMP

29 July 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co US Court of

Appeals Affirms Validity of Strattera Patent

28 July 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Bydureon Reply

Submitted To FDA

22 July 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Cymbalta

Chronic Pain CHMP Opinion

21 July 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Reports

Second-Quarter 2011 Results

1 July 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Walsh

Appointed to Company's Executive Committee

30 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co 2011 Lilly

Investment Community Meeting

27 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co BYDUREON Not

Associated with Relevant QT Prolongation

27 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co BYETTA Lower

Likelihood of Heart Failure

27 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Effect of

BYDUREON on A1C and Weight

27 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Once-Monthly

EXENATIDE Improved Glucose Control

24 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Linagliptin

recommended in Europe for Type II diabetes

21 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Dividend

Declaration - Dividend Declaration

9 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co US Court Rules

in Favor of Lilly in Amylin Litigation

8 June 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co FDA Approves

Updates to Lillys Humalog Label

26 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Comments

on Court Ruling in Amylin Litigation

23 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly &

Investor Grp Form Critical Care Co BioCritica

19 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co ASCO 2011

Cixutumumab Release

19 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co ASCO 2011 BAFF

Release

17 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Provides

Its Perspective in Re to Amylin Lawsuit

16 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Statement in

Response to Amylin Lawsuit - Response to

16 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co ASCO 2011

Pipeline

16 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co ASCO 2011

Branded Products

3 May 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Tradjenta

Approval

28 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly

Maintains Patent Exclusivity for Cymbalta

26 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly

Medtronic Collaboration

19 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Receives

Response Letter from FDA for Liprotamase

19 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Dividend

Declaration - Dividend Declaration

18 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co 1st Quarter

Results- 1st Quarter Results

18 April 2011 Eli Lilly and Company - Issuer Document- Proxy Form

18 April 2011 Eli Lilly and Company - Issuer Document- Proxy Form

15 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co BYDUREON

Recommended For Approval In Europe

7 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Public Alert

Press Release Q111

4 April 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Axiron®

topical solution CIII

18 March 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Amyvid FDA

Action

14 March 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co Lilly Makes

Offer to Acquire Janssen Animal Health - Offer

3 March 2011 Eli Lilly and Company - DJ Lilly (Eli) & Co DURATION-6

Top-Line Study Results Announced

24 February 2011 Eli Lilly and Company - Issuer Document - Prospectus

(excluding RNA)

Full details of the above filings can be found on the National Storage Mechanism's website at http://www.morningstar.co.uk/uk/NSM.

2. FILINGS IN THE UNITED STATES

The Company also submitted the following filings with the United States Securities and Exchange Commission ("SEC") in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having securities registered under the U.S. Securities Exchange Act 1934:


    Filing Date      Forms                 Description               SEC Filing 
                                                                      Group    

24 February 2012 10-K Annual report which provides a Annual


                             comprehensive overview of the company   Filings   
                             for the past year                                 

16 February 2012 SC 13G/A Statement of acquisition of SC 13


                             beneficial ownership by individuals               
                             (Amendment)                                       

16 February 2012 5 Annual statement of changes in 3,4,5

beneficial ownership of securities

15 February 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

13 February 2012 SC 13G/A Statement of acquisition of SC 13


                             beneficial ownership by individuals               
                             (Amendment)                                       

10 February 2012 SC 13G/A Statement of acquisition of SC 13


                             beneficial ownership by individuals               
                             (Amendment)                                       

3 February 2012 PRE 14A Other preliminary proxy statements Proxy

Statement

2 February 2012 5 Annual statement of changes in 3,4,5

beneficial ownership of securities

2 February 2012 5 Annual statement of changes in 3,4,5

beneficial ownership of securities

2 February 2012 5 Annual statement of changes in 3,4,5

beneficial ownership of securities

2 February 2012 5 Annual statement of changes in 3,4,5

beneficial ownership of securities

2 February 2012 4/A Statement of changes in beneficial 3,4,5

ownership of securities - Amendment

2 February 2012 4/A Statement of changes in beneficial 3,4,5

ownership of securities - Amendment

2 February 2012 4/A Statement of changes in beneficial 3,4,5

ownership of securities - Amendment

2 February 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

2 February 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

2 February 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

2 February 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

2 February 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

2 February 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

2 February 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

31 January 2012 8-K Report of unscheduled material events Current

or corporate event Reports

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

11 January 2012 3 Initial statement of beneficial 3,4,5

ownership of securities

11 January 2012 3 Initial statement of beneficial 3,4,5

ownership of securities

6 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

5 January 2012 8-K/A Report of unscheduled material events Current

or corporate event - Amendment Reports

5 January 2012 8-K Report of unscheduled material events Current

or corporate event Reports

3 January 2012 4 Statement of changes in beneficial 3,4,5

ownership of securities

20 December 2011 4/A Statement of changes in beneficial 3,4,5

ownership of securities - Amendment

14 December 2011 3 Initial statement of beneficial 3,4,5

ownership of securities

14 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

12 December 2011 8-K Report of unscheduled material events Current

or corporate event Reports

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4/A Statement of changes in beneficial 3,4,5

ownership of securities - Amendment

1 December 2011 4/A Statement of changes in beneficial 3,4,5

ownership of securities - Amendment

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 December 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

21 November 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

14 November 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

2 November 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

28 October 2011 10-Q Quarterly report which provides a Quarterly


                             continuing view of a company's          Filings   
                             financial position                                

20 October 2011 8-K Report of unscheduled material events Current

or corporate event Reports

13 October 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

3 October 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

3 October 2011 4/A Statement of changes in beneficial 3,4,5

ownership of securities - Amendment

30 September 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

14 September 2011 8-K/A Report of unscheduled material events Current

or corporate event - Amendment Reports

14 September 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

12 September 2011 UPLOAD SEC-generated letter Other

1 September 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

31 August 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

12 August 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

10 August 2011 CORRESP Correspondence Other

3 August 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

29 July 2011 10-Q Quarterly report which provides a Quarterly


                             continuing view of a company's          Filings   
                             financial position                                

25 July 2011 CORRESP Correspondence Other

21 July 2011 8-K Report of unscheduled material events Current

or corporate event Reports

13 July 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

13 July 2011 UPLOAD SEC-generated letter Other

8 July 2011 3 Initial statement of beneficial 3,4,5

ownership of securities

8 July 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 July 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

30 June 2011 8-K Report of unscheduled material events Current

or corporate event Reports

28 June 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

22 June 2011 CORRESP Correspondence Other

22 June 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

15 June 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

2 June 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

1 June 2011 CORRESP Correspondence Other

24 May 2011 UPLOAD SEC-generated letter Other

18 May 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

18 May 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

13 May 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

10 May 2011 CORRESP Correspondence Other

2 May 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

29 April 2011 10-Q Quarterly report which provides a Quarterly


                             continuing view of a company's          Filings   
                             financial position                                

19 April 2011 8-K Report of unscheduled material events Current

or corporate event Reports

18 April 2011 8-K Report of unscheduled material events Current

or corporate event Reports

14 April 2011 CORRESP Correspondence Other

13 April 2011 UPLOAD SEC-generated letter Other

12 April 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

4 April 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

14 March 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

10 March 2011 SC 13G/A Statement of acquisition of SC 13


                             beneficial ownership by individuals -             
                             Amendment                                         

8 March 2011 ARS Annual Report to Security Holders Annual

Filings

8 March 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

7 March 2011 DEF 14A Other definitive proxy statements Proxy

Statements

2 March 2011 4 Statement of changes in beneficial 3,4,5

ownership of securities

24 February 2011 S-8 Securities to be offered to employees Registration

in employee benefit plans Statements

Full details of the above regulatory announcements can be found on the SEC website at http://www.sec.gov.

CONTACT:

Jamie E. Haney

Counsel - Corporate Securities and Assistant Secretary

(317) 277-3278

(317) 407-1288 (M)

haney_jamie_e@lilly.com

LONDON\AVINCE\23599249.01

9

1233315-v2\NYCDMS

LONDON\AVINCE\23599249.01

END

-0- Jan/24/2013 18:02 GMT

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement